Fennec Pharmaceuticals (FENC) Non Operating Income (2010 - 2026)

Fennec Pharmaceuticals (FENC) has 16 years of Non Operating Income data on file, last reported at -$2.1 million in Q4 2025.

• Quarterly Non Operating Income fell 210.06% year-over-year to -$2.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$3.4 million (down 27.06% YoY) and the FY2025 annual result came in at -$3.4 million, down 27.06% from the prior year.
• Non Operating Income declined to -$2.1 million in Q4 2025, from -$449000.0 in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $190000.0 in Q1 2021 to a low of -$2.1 million in Q4 2025.
• A 5-year average of -$525700.0 and a median of -$481500.0 in 2024 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2021 — Non Operating Income soared 2011.11% — and 2022, when it plunged 1483.33%.
• Tracing FENC's Non Operating Income over 5 years: stood at -$220000.0 in 2021, then tumbled by 228.18% to -$722000.0 in 2022, then slipped by 19.67% to -$864000.0 in 2023, then rose by 20.6% to -$686000.0 in 2024, then plunged by 210.06% to -$2.1 million in 2025.
• The last three Non Operating Income figures came in at -$2.1 million (Q4 2025), -$449000.0 (Q3 2025), and -$420000.0 (Q2 2025), per Business Quant data.